June 22, 1995New England Journal of Medicine
The Optimal Duration of Anticoagulant Therapy for Venous Thrombosis
Why the study?
Does oral anticoagulant therapy prevent recurrent deep-vein thrombosis in patients with deep-vein thrombosis?
Population
Patients with deep-vein thrombosis
Comparison
Oral anticoagulant therapy vs No oral anticoagulant therapy
Design
Editorial
Follow-up
3 months
Authors
Discussion
Loading...
Member takes
Implication
Oral anticoagulant therapy following heparin significantly reduces the 3-month incidence of recurrent deep-vein thrombosis, though the optimal duration remains an area of discussion.
Key Points
- The study aims to identify the optimal duration of anticoagulant therapy in patients with deep-vein thrombosis to minimize the risk of recurrence.
- Reviewed results from randomized trials over 20 years focusing on anticoagulant therapy for deep-vein thrombosis.
- Assessed the impact of a five-day heparin treatment followed by oral anticoagulants.
- Evaluated the incidence of recurrent deep-vein thrombosis over a three-month period.
- Incidence of recurrent deep-vein thrombosis was over 25% without continued anticoagulant treatment.
- In treated patients, the incidence of recurrence decreased to less than 4%.
Structured PICO
Does oral anticoagulant therapy prevent recurrent deep-vein thrombosis in patients with deep-vein thrombosis?
P
Population
Patients with deep-vein thrombosis
I
Intervention
Oral anticoagulant therapy
C
Comparator
No oral anticoagulant therapy
O
Outcome
Recurrent deep-vein thrombosishard clinical
Oral anticoagulant therapy following heparin significantly reduces the 3-month incidence of recurrent deep-vein thrombosis, though the optimal duration remains an area of discussion.
Cite This Study
Jack Hirsh (1995) studied this question.